0  -0%
Previous Close 1.65
Open 1.67
Price To Book 2.65
Market Cap 82544362
Shares 50,148,458
Volume 632,099
Short Ratio
Av. Daily Volume 887,901

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data presented at ECCMID April 13, 2019.
SCY-078 - oral - CARES
Candida Auris
Phase 2 trial initiated 3Q 2018.
Ibrexafungerp (SCY-078)
Invasive aspergillosis
Phase 3 data due 1H 2020.
SCY-078 - oral ibrexafungerp - VANISH
Vulvovaginal candidiasis (VVC)
Phase 3 open label interim data released January 30, 2019 - 11/17 partial or complete responses. Data to be presented at ECCMID April 16, 2019.
SCY-078 - oral (FURI)
Invasive candidiasis
Phase 3 trial to commence 1H 2019.
SCY-078 - ibrexafungerp
Recuurent Vulvovaginal candidiasis (VVC)

Latest News

  1. SCYNEXIS to Discuss ECCMID 2019 Clinical Data, Including Successful Case Studies in Candida auris and Other Difficult-to-Treat Infections, on Conference Call
  2. The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
  3. Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
  4. SCYNEXIS Commends the New York Times for its Reporting on Candida auris and Other Drug-Resistant Pathogens
  5. SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID
  6. SCYNEXIS, Inc. to Present at Upcoming Investor Conferences
  7. SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update
  8. SCYNEXIS is Retiring Existing Term Loan Through a Lower-Interest and Longer-Term Convertible Note
  9. Do Institutions Own Shares In SCYNEXIS, Inc. (NASDAQ:SCYX)?
  10. SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019
  11. 4 Biotech Stocks Making Moves On Thursday (1/31/19)
  12. SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies
  13. SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors
  14. Does SCYNEXIS, Inc.’s (NASDAQ:SCYX) CEO Salary Reflect Performance?
  15. Antimicrobials Working Group Announces Updates to Leadership Team
  16. The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO
  17. SCYNEXIS Provides Year-end Update and Outlines Plans for 2019
  18. Report: Developing Opportunities within ReWalk Robotics, ImmuCell, SCYNEXIS, Fuel Tech, Garrison Capital, and AMREP — Future Expectations, Projections Moving into 2018
  19. Scynexis (SCYX) Reports Q3 Loss, Tops Revenue Estimates